High- Versus Low-Dose ACE Inhibitor Therapy in Chronic Heart Failure

Abstract

Spanish

French

OBJECTIVE

To discuss the controversy associated with the optimal dosing of angiotensin-converting enzyme (ACE) inhibitors in the management of patients with systolic heart failure; specifically, to review data related to the use of high-dose ACE inhibitors related to both neurohormonal and clinical outcomes associated with doses similar to, lower than, and higher than those used in the large, randomized clinical trials.

DATA SOURCES

Primary, review, and meta-analysis articles were identified by MEDLINE search (1987–September 2002) and through secondary sources.

STUDY SELECTION AND DATA EXTRACTION

All of the articles identified from the data sources were evaluated, and all information deemed relevant was included in this discussion. All available comparative dose trials, both prospective and retrospective, were evaluated for clinical and neurohormonal outcomes.

DATA SYNTHESIS

The majority of data comparing the effect of high- with low-dose ACE inhibitors on neurohormonal outcomes demonstrate dose-related reduction in various neurohormonal measurements including plasma ACE, aldosterone, atrial natriuretic peptide, B-type natriuretic peptide, and interleukin-6 levels. Clinical endpoints including New York Heart Association class and heart failure—related hospitalizations were reduced by higher doses, but a dose-related survival benefit has not been demonstrated. Differences in duration of therapy and study design may account for variability in neurohormonal and morbidity results among various studies.

CONCLUSIONS

Despite documented underutilization in clinical practice of doses of ACE inhibitors demonstrated in large controlled trials to improve morbidity and mortality, clinicians should attempt to reach these target doses if possible in patients with heart failure. Higher doses may improve surrogate markers for heart failure without impacting survival.

Keywords

angiotensin-converting enzyme inhibitors optimal dosing systolic heart failure

Get full access to this article

View all access options for this article.

References

1. 2001 Heart and stroke statistical update. Dallas: American Heart Association, 2000.

2. Ho

KKL

, Pinsky

, Kannel

, Levy

. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol 1993; 22: 6A–13A.

3. American Heart Association. Heart disease and stroke statistics-2004 update. www.americanheart.org/downloadable/heart/1075102824882HDSStats2004UpdateREV1-23-04.pdf (accessed 2004 Mar 10).

4. Garg

, Yusuf

. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995; 273: 1450–6.

5. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145–53.

6. McMurray

. Failure to practice evidence-based medicine: why do physicians not treat patients with heart failure with angiotensin-converting enzyme inhibitors? Eur Heart J 1998: 19(suppl L):L15–21.

7. Bungard

, McAlister

, Johnson

, Tsuyuki

. Underutilization of ACE inhibitors in patients with congestive heart failure. Drugs 2001; 61: 2021–33.

8. Tang

WHW

, Francis

. Polypharmacy of heart failure: creating a rational pharmacotherapeutic protocol. Cardiol Clin 2001; 19: 583–96.

9. Pfeffer

, Braunwald

, Moye

, Basta

, Brown

Jr , Cuddy

. et al. Effects of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992; 327: 669–77.

10.

10. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316: 1429–35.

11.

11. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327: 685–91.

12.

12. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and heart failure. N Engl J Med 1991; 325: 293–302.

13.

13. Cohn

, Johnson

, Ziesche

, Cobb

, Francis

, Tristani

, A comparison of enalapril with hydralazine—isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325: 303–10.

14.

14. Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on morbidity and mortality of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821–8.

15.

15. The NETWORK Investigators. Clinical outcome with enalapril in symptomatic chronic heart failure: a dose comparison. Eur Heart J 1998; 19: 481–9.

16.

16. Packer

, Poole-Wilson

, Armstrong

, Cleland

JGF

, Horowitz

, Massie

, Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation 1999; 100: 2312–8.

17.

17. Clement

, De Buyzere

, Tomas

, Vanavermaete

. Long-term effects of clinical outcome with low and high dose in the Captopril in Heart Insufficient Patients Study (CHIPS). Acta Cardiol 2000; 55: 1–7.

18.

18. Berger

, Kuchling

, Frey

, Kozanly

, Pacher

, Stanek

. ACE inhibitor dosage at the time of listing predicts survival. J Heart Lung Transplant 2000; 19: 127–33.

19.

19. Nanas

, Alexopopulos

, Anastasiou-Nana

, Karidis

, Tirologos

, Zobolos

, Outcomes of patients with congestive heart failure treated with standard versus high doses of enalapril: a multicenter study. J Am Coll Cardiol 2000; 36: 2090–5.

20.

20. Eichhorn

, Bristow

. Medical therapies can improve the biological properties of the chronically failing heart: a new era in the treatment of heart failure. Circulation 1996; 94: 2285–96.

21.

21. Frances

. Changing the remodeling process in heart failure: basic mechanisms and laboratory results. Curr Opin Cardiol 1998; 13: 156–61.

22.

22. Pacher

, Globits

, Bergler-Klein

, Teufelsbauer

, Wutte

, Baumgartner

, Clinical and neurohormonal response of patients with severe congestive heart failure treated with two different captopril dosages. Eur Heart J 1993; 14: 273–8.

23.

23. Davidson

, Coutie

, Webb

, Struthers

. Hormonal and renal differences between low dose and high dose angiotensin converting inhibitor treatment in patients with chronic heart failure. Heart 1996; 75: 576–81.

24.

24. Duchman

, Thohan

, Kalra

, Torre-Amione

. Endothelin-1: a new target of therapeutic intervention for the treatment of heart failure. Curr Opin Cardiol 2000; 15: 136–40.

25.

25. The RALES Investigators. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure. (The Randomized Aldactone Evaluation Study [RALES]). Am J Cardiol 1996; 78: 902–7.

26.

26. Pacher

, Stanek

, Globits

, Berger

, Hulsmann

, Wutte

, Effects of two different enalapril dosages on clinical, haemodynamic and neurohormonal response of patients with severe congestive heart failure. Eur Heart J 1996; 17: 1223–32.

27.

27. Brunner-LaRocca

, Weilenmann

, Kiowski

, Maly

, Candinas

, Follath

. Within-patient comparison of effects of different dosages of enalapril on functional capacity and neurohormonal levels in patients with chronic heart failure. Am Heart J 1999; 138: 654–62.

28.

28. Krown

, Page

, Nguyen

, Zechner

, Gutierrez

, Comstock

, Tumor necrosis factor alpha—induced apoptosis in cardiac myocytes. J Clin Invest 1996; 98: 2854–65.

29.

29. Kunisada

, Hirota

, Fujio

, Matsui

, Tani

, Yamauchi-Takihara

, Activation of JAK-STAT and MAP kinases by leukemia inhibitory factor through gp130 in cardiac myocytes. Circulation 1996; 94: 2626–32.

30.

30. Gullestad

, Aukrust

, Ueland

, Espevik

, Yee

, Vagelos

, Effect of high- versus low-dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure. J Am Coll Cardiol 1999; 34: 2061–7.

31.

31. Tang

WHW

, Vagelos

, Yee

, Benedict

, Wilson

, Liss

, Neurohormonal and clinical response to high- versus low-dose enalapril therapy in chronic heart failure. J Am Coll Cardiol 2002; 39: 70–8.

32.

32. Struthers

. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure. J Card Fail 1996; 2: 47–54.

33.

33. ISIS-4 Collaborative Group. A randomized factorial trial assessing early oral captopril, oral mononitrate and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995; 345: 669–85.

34.

34. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult. J Am Coll Cardiol 2001; 38: 2101–13.

35.

35. Packer

, Cohn

. Consensus Recommendations for the Management of Chronic Heart Failure. Am J Cardiol 1999; 83: 10A–30A.

36.

36. Chen

, Wang

, Radford

, Krumholz

. Angiotensin-converting enzyme inhibitor dosages in elderly patients with heart failure. Am Heart J 2001; 141: 410–7.

37.

37. Cohn

, Toginoni

. A randomized trial of the angiotensin receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345: 167–75.